Jack Chapman, MD
Ophthalmology · Gainesville, GANPI 1689662751
Payments from drug & device makers
Across 543 payments — averaging $562.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$145K
- Alcon Research LLC$62K
- Lensar, Inc.$54K
- Alcon$26K
- Bausch & Lomb Americas Inc.$5K
- Nordic Pharma, Inc.$3K
- plus $10K from 27 others
What the payments were for
- Consulting fees$71,90630%
- Speaking & faculty fees$123,57251%
- Travel & lodging$27,66011%
- Food & beverage$20,2238%
- Education$1590%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 184 | $145,234 |
| Alcon Research LLC | 25 | $62,105 |
| Lensar, Inc. | 40 | $53,730 |
| Alcon | 102 | $25,570 |
| Bausch & Lomb Americas Inc. | 18 | $4,941 |
| Nordic Pharma, Inc. | 2 | $3,375 |
| Tearlab Corp | 11 | $2,730 |
| Biotissue Holdings Inc. | 9 | $1,707 |
| Rxsight Inc | 12 | $947 |
| AbbVie(2 entities) | 31 | $577 |
| Eyevance Pharmaceuticals LLC | 8 | $561 |
| Oyster Point Pharma, Inc. | 6 | $423 |
| Dompe US, Inc. | 9 | $399 |
| Rayner Intraocular Lenses Limited | 9 | $328 |
| Eyepoint US, Inc. | 5 | $321 |
| Tarsus Pharmaceuticals, Inc. | 12 | $301 |
| Johnson & Johnson Surgical Vision, Inc. | 7 | $243 |
| Amgen(2 entities) | 7 | $241 |
| Sight Sciences, Inc. | 4 | $194 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $190 |
| NEW World Medical,inc. | 2 | $188 |
| Glaukos Corporation | 5 | $156 |
| Kala Pharmaceuticals, Inc. | 8 | $115 |
| Ocular Therapeutix, Inc. | 3 | $113 |
| Mallinckrodt Hospital Products Inc. | 5 | $94 |
| Astellas Pharma US Inc | 1 | $75 |
| Aerie Pharmaceuticals, Inc. | 4 | $74 |
| Harrow Eye, LLC | 2 | $58 |
| Omeros Corporation | 1 | $57 |
| Carl Zeiss Meditec USA, Inc. | 3 | $56 |
| Quidel Corporation | 2 | $54 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BROMSITE$75,092
- CEQUA$67,387
- LENSAR LASER SYSTEM$53,104
- AcrySof IQ PanOptix$14,207
- AcrySof IQ VIVITY IOL$12,400
- ENVISTA ENVY IOL$4,200
- Lacrifill$3,375
- Clareon$1,850
- PanOptix$1,470
- SCOUTPRO$1,400
- ScoutPro Osmolarity System$806
- Centurion$776
- RXSIGHT CONTACT LENS$768
- RXSIGHT INJECTOR CARTRIDGE$768
- RXSIGHT INJECTOR HANDPIECE$768
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$768
- Wavelight Refractive Suite$650
- SMART Suite$490
- XELPROS$465
- LIGHT ADJUSTABLE LENS (LAL)$399
How this compares
$305,191 in reported general payments places this provider in the 95th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 55 | $25,827 |
| RestasisCyclosporine | 22 | $21,272 |
| Latanoprost | 523 | $6,870 |
| Travoprost | 33 | $6,081 |
| AzoptBrinzolamide | 11 | $4,131 |
| RocklatanNetarsudil Mesylat/Latanoprost | 11 | $3,632 |
| Brimonidine Tartrate | 104 | $3,363 |
| ZioptanTafluprost/Pf | 11 | $2,774 |
| Timolol Maleate | 105 | $2,032 |
| Dorzolamide Hcl | 105 | $1,549 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 62 | $953 |
| Prednisolone Acetate | 27 | $737 |
| Ketorolac Tromethamine | 14 | $369 |
| Levobunolol Hcl | 13 | $231 |
| ErythromycinErythromycin Base | 12 | $100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis | $577 | $47,09977 claims |
| AlconAzopt | $25,570 | $4,13111 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $74 | $3,63211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Gainesville
- Clayton BlehmGainesville$1.7M
- Zachary BalestGainesville$50K
- Dennis MarcusAugusta$9.2M
- Robert StoltzMarietta$3.9M
- Eugene McLaurinSavannah$3.3M
- Lakshmana KooragayalaMarietta$1.4M
- Douglas DayAtlanta$1.1M
- Jennifer KimMorrow$989K
- Thomas AabergAtlanta$959K
- Gagan SawhneyAtlanta$874K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.